Retour sur lavenir.net
   ARGENX SE 671.200 € (-2,50 %)     TESSENDERLO 21.400 € (-1,38 %)     ELIA GROUP 137.000 € (-1,65 %)     LOTUS BAKERIES 10 740.000 € (0,00 %)     UCB 232.800 € (-1,36 %)     D'IETEREN GROUP 179.600 € (-2,39 %)     CENERGY 24.660 € (-2,68 %)     UMICORE 21.080 € (+1,44 %)     ECONOCOM GROUP 1.400 € (0,00 %)     AGEAS 67.300 € (0,00 %)     AB INBEV 67.800 € (-2,25 %)     AEDIFICA 72.400 € (-0,48 %)     EVS BROADC.EQUIPM. 37.350 € (-0,13 %)     KBC 115.700 € (-0,30 %)     MELEXIS 77.000 € (+0,39 %)     AGFA-GEVAERT 0.463 € (0,00 %)     RETAIL ESTATES 67.500 € (-0,88 %)     FAGRON 24.550 € (-1,21 %)     BARCO 9.005 € (-1,96 %)     SHURGARD 26.250 € (+0,57 %)     ASCENCIO 49.600 € (-1,20 %)     SYENSQO 57.250 € (-2,64 %)     AZELIS GROUP 10.510 € (-2,69 %)     COLRUYT 32.220 € (-2,54 %)     TUBIZE-FIN 200.200 € (-0,60 %)     ONTEX GROUP 2.855 € (-1,38 %)     TITAN S.A. 49.880 € (+0,97 %)     CARE PROPERTY INV. 13.080 € (-0,15 %)     WDP 22.420 € (-0,88 %)     KINEPOLIS GROUP 30.200 € (-0,49 %)     BEKAERT 43.400 € (-1,36 %)     ACKERMANS V.HAAREN 291.800 € (-1,55 %)     MONTEA 68.900 € (-2,68 %)     DEME GROUP 201.500 € (-0,98 %)     DECEUNINCK 2.050 € (-0,49 %)     IMMOBEL 21.100 € (-0,94 %)     ONWARD MEDICAL 2.685 € (-0,56 %)     JENSEN-GROUP 70.200 € (-0,28 %)     EKOPAK 4.450 € (-0,11 %)     SIPEF 99.800 € (-1,58 %)     ENERGYVISION 13.200 € (+2,33 %)     HOME INVEST BE. 19.160 € (-1,14 %)     MATERIALISE 4.600 € (-4,96 %)     OXURION 0.004 € (-5,00 %)     TINC 12.040 € (-1,15 %)     WERELDHAVE BELGIUM 53.000 € (-0,75 %)     VAN DE VELDE 31.000 € (+1,64 %)     CIE BOIS SAUVAGE 323.000 € (-0,92 %)     VASTNED 28.650 € (+0,17 %)     VIOHALCO 17.640 € (+1,61 %)     EXMAR 10.800 € (-0,46 %)     BQUE NAT. BELGIQUE 375.000 € (-1,32 %)     KBC ANCORA 79.900 € (-0,12 %)     BANQUP GROUP 2.570 € (+7,08 %)     RECTICEL 10.380 € (0,00 %)     XIOR 27.800 € (+0,36 %)     CAMPINE 224.000 € (-1,75 %)     GIMV 48.900 € (+0,62 %)     PROXIMUS 6.565 € (-0,61 %)     CMB.TECH 12.480 € (-1,27 %)  
   BOLLORE 5.300 € (-2,21 %)     STMICROELECTRONICS 48.255 € (-0,51 %)     PUBLICIS GROUPE SA 81.720 € (+0,05 %)     VALNEVA 2.450 € (+5,69 %)     ORANGE 17.670 € (-2,48 %)     ASM INTERNATIONAL 858.800 € (-1,45 %)     AYVENS 11.220 € (-1,58 %)     EUROFINS SCIENT. 59.720 € (-0,47 %)     ADP 108.100 € (-0,09 %)     AHOLD DEL 37.670 € (-2,10 %)     SODEXO 43.060 € (-2,76 %)     DASSAULT AVIATION 298.600 € (-2,99 %)     L'OREAL 367.000 € (-1,71 %)     RENAULT 31.140 € (+1,43 %)     NN GROUP 75.560 € (-0,18 %)     SHELL PLC 36.090 € (-2,85 %)     LVMH 478.300 € (+0,91 %)     ENGIE 26.860 € (-2,58 %)     AXA 41.580 € (-0,53 %)     UNIBAIL-RODAMCO-WE 102.150 € (-2,11 %)     HERMES INTL 1 702.000 € (+1,82 %)     SOCIETE GENERALE 69.630 € (-0,53 %)     TOTALENERGIES 75.270 € (-1,93 %)     CREDIT AGRICOLE 17.155 € (-0,55 %)     AIR LIQUIDE 176.700 € (-1,99 %)     GALAPAGOS 23.580 € (-4,22 %)     ARGAN 61.800 € (-1,12 %)     AKZO NOBEL 51.260 € (-0,16 %)     CSG 16.146 € (-5,34 %)     AIRBUS 183.440 € (-2,68 %)     LAGARDERE SA 18.140 € (-0,11 %)     SANOFI 73.740 € (-1,21 %)     NANOBIOTIX 35.840 € (+3,29 %)     HEIJMANS KON 90.100 € (-0,28 %)     ING GROEP N.V. 25.750 € (+0,86 %)     SOITEC 150.750 € (+2,66 %)     ASML HOLDING 1 300.000 € (-0,38 %)     MICHELIN 32.040 € (-0,28 %)     VIVENDI SE 2.070 € (+1,67 %)     DBV TECHNOLOGIES 3.360 € (-2,61 %)     STELLANTIS NV 6.404 € (-1,11 %)     SCHNEIDER ELECTRIC 275.200 € (-2,65 %)     PROSUS 41.960 € (+0,19 %)     AIR FRANCE -KLM 10.620 € (+3,06 %)     DANONE 63.280 € (-2,53 %)     ALSTOM 17.535 € (-0,26 %)     VINCI 131.550 € (-1,46 %)     VEOLIA ENVIRON. 35.910 € (-0,80 %)     CAPGEMINI 104.900 € (-0,05 %)     CARVOLIX 3.160 € (-0,94 %)     GROUPE GUILLIN 22.900 € (-0,87 %)     SAFE 0.690 € (-8,00 %)     SAINT GOBAIN 80.180 € (-0,07 %)     APERAM 48.540 € (-1,78 %)     SAFRAN 294.800 € (-0,64 %)     ARCELORMITTAL SA 53.320 € (-0,45 %)     BASTIDE LE CONFORT 26.600 € (-0,56 %)     KALRAY 7.960 € (-5,46 %)     ROCTOOL 1.320 € (+15,79 %)     AEGON 7.102 € (-0,87 %)  
News Réglementées
07/05/2026 20:42

RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Quarter Results/Miscellaneous
RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026

07.05.2026 / 20:42 CET/CEST
The issuer is solely responsible for the content of this announcement.


CORPORATE NEWS

First quarter of 2026

RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026
 

  • Group optimises outpatient and inpatient care structures
  • Number of patients treated increased by 7.4 %, while the reported consolidated revenue is at EUR 436.1 million
  • Current financial year affected by upcoming reforms

Bad Neustadt, 7 May 2026 – RHÖN-KLINIKUM AG entered financial year 2026 with stable business performance. Consolidated revenue of EUR 436.1 million was slightly above the prior year's figure (Q1 2025: EUR 414.7 million), while EBITDA amounted to EUR 30.2 million (Q1 2025: EUR 22.6 million). Net income totalled EUR 13.1 million (Q1 2025: EUR 7.3 million). From January to March, the Group's clinics and medical centres treated 258,027 patients on an inpatient and outpatient basis, an increase of 7.4 % (Q1 2025: 240,137).

The hospital sites of the company continue to see dynamic growth. In addition to the major investments in state-of-the-art medical technology planned at all hospital sites in 2026, we are further expanding our medical and therapeutic care for patients throughout the Group.

In the first quarter of 2026, the operating business of Ortho Centrum Saale MVZ GmbH was integrated into the Group and its results included in the consolidated financial statements. The company, with six doctor’s practices in the specialist fields of orthopaedics, trauma surgery, surgery, sports medicine, sports trauma medicine and neurosurgery, was acquired to strengthen the RHÖN-Campus concept in Bad Neustadt as well as growth prospects in the clinical and outpatient sector in the region of Rhön-Grabfeld.

Outlook for 2026

For the coming financial year, we expect revenues of EUR 1.7 billion within
a range of plus or minus 5 %. For earnings before interest, tax and depreciation/amortisation (EBITDA), we expect a level of between
EUR 110 million and EUR 125 million. In addition to the financial performance indicators, we also take account of the non-financial performance indicators
of number of cases and cost weights in the management of the company and expect these to show a moderate improvement over the previous year.

The current financial year is expected to be significantly affected by legislative procedures and its corresponding substantial uncertainties. In particular, the Hospital Reform Adjustment Act (KHAG), which entered into force on 15 April 2026, as well as the implications of the Statutory Health Insurance Financial Stabilization Act (GKV-Finanzstabilisierungsgesetz), while aiming to further strengthen quality and efficiency within the healthcare system, simultaneously increase financial pressure on hospitals in the short term.

The Group’s forecast is therefore subject to considerable uncertainties. The cumulative impact of ongoing regulatory interventions, the implementation of the German hospital reform, and potential further adjustments by the legislature can currently not be reliably estimated. In addition to these developments global crises and economic pressures, which manifest – among other developments – in price increases, supply restrictions, and volatile operating conditions.

Considering these aspects, it will be decisive whether further adjustments to the ongoing reforms and supporting measures will be implemented to enable hospitals providing economically sustainable and high-quality patient care in the future.

Dr. Stefan Stranz, Member of the Executive Board of RHÖN-KLINIKUM AG: “Reliable medical care requires economically stable hospitals. Particularly against the backdrop of current reforms, it will be crucial whether financing and regulatory frameworks continue to enable hospitals to fulfill their mandate providing care in a sustainable manner.”

Dr. Gunther K. Weiß, Member of the Executive Board RHÖN-KLINIKUM AG: “Our business processes are both efficient and flexible. The close and trustworthy collaboration within the ASKLEPIOS Group plays a significant role in these. At the same time, the impact of current reforms and further regulatory interventions remains subject to considerable uncertainty. To permanently ensure high-quality and reliable patient care, hospitals require stable economic and political conditions.”

The Quarterly Statement – Q1 2026 – is published in the Internet.

CONTACT

RHÖN-KLINIKUM AG | Head of Group Finance
Norman Dittes | T. +49 9771 65-12210 | norman.dittes@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Corporate Communications
Heike Ochmann | T. +49 9771 65-12130 | heike.ochmann@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale

 

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. With Campus Bad Neustadt, Zentralklinik
Bad Berka, Klinikum Frankfurt (Oder) as well as the Giessen and Marburg University Hospitals (UKGM), the company has
five highly specialised maximum- and intermediate-care hospitals. As a modern, diverse and future-oriented company,
RHÖN-KLINIKUM AG is attractive both as an employer and training centre. With over 19,100 employees, the Group offers excellent medical care with a direct tie-in to research and teaching. Each year, over 938,000 patients are treated in the
Group’s hospitals and medical care centres (MVZs) on an outpatient and inpatient basis. RHÖN-KLINIKUM AG is a company
of the ASKLEPIOS Group. www.rhoen-klinikum-ag.com



07.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language:English
Company:RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale
Germany
Phone:+49 (0)9771 - 65-0
Fax:+49 (0)9771 - 97 467
E-mail:rka@rhoen-klinikum-ag.com
Internet:www.rhoen-klinikum-ag.com
ISIN:DE0007042301
WKN:704230
Listed:Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate BSX
EQS News ID:2323556

 
End of NewsEQS News Service

2323556  07.05.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière